{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:57:55Z","timestamp":1792252675412,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["NCT02028884"],"award-info":[{"award-number":["NCT02028884"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["NCT02073279"],"award-info":[{"award-number":["NCT02073279"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.msard.2025.106444","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T18:26:46Z","timestamp":1745087206000},"page":"106444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2091-8201","authenticated-orcid":false,"given":"Benjamin M.","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Blondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Burdeska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocent","family":"Ngwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Klingelschmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Triyatni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2025.106444_bib0001","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000977","article-title":"Rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody-associated diseases","volume":"8","author":"Avouac","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"22","key":"10.1016\/j.msard.2025.106444_bib0002","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106444_bib0003","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106444_bib0004","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/pds.4165","article-title":"Quantification of missing prescriptions in commercial claims databases: results of a cohort study","volume":"26","author":"Cepeda","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.msard.2025.106444_bib0005","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2014.08.202","article-title":"Risk factors for immunosuppression-associated infections in aquaporin-4 antibody mediated neuromyelitis optica spectrum disorders","volume":"275","author":"Cheng","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"10206","key":"10.1016\/j.msard.2025.106444_bib0006","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.msard.2025.106444_bib0007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/nau.22667","article-title":"Voiding dysfunction in patients with neuromyelitis optica spectrum disorders","volume":"35","author":"de Carvalho","year":"2016","journal-title":"Neurourol. Urodyn."},{"issue":"20","key":"10.1016\/j.msard.2025.106444_bib0008","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.msard.2025.106444_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084154","article-title":"Adverse events in NMOSD therapy","volume":"23","author":"Giglhuber","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10132","key":"10.1016\/j.msard.2025.106444_bib0010","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106444_bib0011","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/ITT.S287652","article-title":"Drug treatment of neuromyelitis optica spectrum disorders: out with the old, in with the new?","volume":"10","author":"Held","year":"2021","journal-title":"Immunotargets. Ther."},{"issue":"12","key":"10.1016\/j.msard.2025.106444_bib0012","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1007\/s00415-020-10235-5","article-title":"Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder","volume":"268","author":"Holmoy","year":"2021","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106444_bib0013","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin. Med. (Lond)"},{"issue":"1","key":"10.1016\/j.msard.2025.106444_bib0014","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.msard.2025.106444_bib0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation."},{"issue":"2","key":"10.1016\/j.msard.2025.106444_bib0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2025.106444_bib0017","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.msard.2025.106444_bib0018","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106444_bib0019","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001179","article-title":"Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience","volume":"9","author":"Kim","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2025.106444_bib0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106444_bib0021","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.msard.2025.106444_bib0022","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/460825","article-title":"Neuromyelitis optica: an antibody-mediated disorder of the central nervous system","author":"Oh","year":"2012","journal-title":"Neurol. Res. Int."},{"key":"10.1016\/j.msard.2025.106444_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2025.106444_bib0024","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2025.106444_bib0025","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106444_bib0026","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200124","article-title":"International delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2025.106444_bib0027","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106444_bib0028","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2025.106444_bib0029","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.msard.2025.106444_bib0030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5603\/PJNNS.a2019.0049","article-title":"Novel emerging treatments for NMOSD","volume":"53","author":"Selmaj","year":"2019","journal-title":"Neurol. Neurochir. Pol."},{"issue":"1","key":"10.1016\/j.msard.2025.106444_bib0031","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12916-016-0673-8","article-title":"Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis","volume":"14","author":"Singh","year":"2016","journal-title":"BMC. Med."},{"issue":"5","key":"10.1016\/j.msard.2025.106444_bib0032","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106444_bib0033","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1177\/13524585211069068","article-title":"The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021","volume":"28","author":"Tur","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"9","key":"10.1016\/j.msard.2025.106444_bib0034","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1177\/13524585211069068","article-title":"The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021","volume":"28","author":"Tur","year":"2022","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2025.106444_bib0035","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2025.106444_bib0036","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1111\/ene.16014","article-title":"Causal associations between prodromal infection and neuromyelitis optica spectrum disorder: a Mendelian randomization study","volume":"30","author":"Wang","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106444_bib0037","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"issue":"9","key":"10.1016\/j.msard.2025.106444_bib0038","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"22","key":"10.1016\/j.msard.2025.106444_bib0039","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106444_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104025","article-title":"Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar","volume":"66","author":"Yamamura","year":"2022","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:40:51Z","timestamp":1762602051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825001865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"alternative-id":["S2211034825001865"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106444","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106444"}}